Quantitative approaches to drug development

We provide consultancy services to help our clients reduce uncertainty in research and regulatory questions, increasing confidence in the development of new medicines that can improve patients’ lives.

Science and Services
Pharmetheus_MIDD_PBPKQSP_Pharmacometrics

About

News

09.04.2025
Dr. Jurij Aguiar Zdovc, consultant at Pharmetheus.
Time to register for the Educational Pharmacometrics Summer Symposium

Don’t miss the chance to attend the fourth annual Educational Pharmacometrics Summer Symposium (EPSS) on June 3, 2025 the Makedonia Palace Hotel, Thessaloniki, Greece. A free symposium including presentations from experts and professionals in the pharmacometrics field, accompanied by case examples presented by student attendees to help you get a wide overview of this exciting field. This fourth EPSS in…

03.04.2025
Pharmetheus-Pattern-203
New publication exploring drug-drug interactions (DDIs) and food effects for Bevurogant (BI 730357), a competitive antagonist of the retinoic acid-related orphan receptor γ (RORγ), investigated as an oral treatment for plaque psoriasis.

This study, published in the special issue of MDPI Pharmaceutics: Advances in Pharmacokinetics and Drug Interactions, explored drug-drug interactions (DDIs) and food effects for Bevurogant (BI 730357), a competitive antagonist of the retinoic acid-related orphan receptor γ (RORγ), investigated as an oral treatment for plaque psoriasis. The publication was co-authored by Dr. Tobias Kanacher, Assoc. Prof Dr. Erik Sjögren, and…

18.03.2025
Pharmetheus-Pattern-211
Exposure‐tumour growth inhibition modelling of brigimadlin using phase I solid tumour data to support phase II dose selection

This research focuses on leveraging quantitative modeling to support dose selection in oncology drug development, presenting development of an exposure-tumour growth inhibition (E-TGI) model to investigate the relationship between brigimadlin exposure and tumour shrinkage using data from a phase I clinical trial. The aim was to support the selection of the recommended phase II dose (RP2D) for brigimadlin, a potent…

How we work

Publications

Explore our scientific publications.

All publications

Explore our web

MartinBergstrand

Model Informed Drug Development (MIDD) consulting services

A quantitative framework to support and inform development program strategies and decisions.

Read more about Model Informed Drug Development (MIDD) consulting services
Sophie-Peigne-2

“Sharing with colleagues is why I love working here”

Sophie Peigné supports clients with expert and strategic advice in pharmacometrics as well as hands-on modeling analyses for compounds in all development phases.

Read more about “Sharing with colleagues is why I love working here”
MatsKarlsson

History of Pharmetheus

Our journey is an exciting one. We began as a start-up that spinned off from Uppsala University. Today, we have grown into a global medium-sized company, adding value to drug development each day.

Read more about History of Pharmetheus